MAPT and Alzheimer disease: An additional mechanism of AST and AST-LI is the downregulation of GSK-3B-induced P-tau and Aβ plaques that underlie the observed improvements in neurotransmitter balance, behavioral scores, synaptic function, and cognitive loss linked to AD.